Clinical Trials Logo

Menorrhagia clinical trials

View clinical trials related to Menorrhagia.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05788172 Completed - Anemia Clinical Trials

Measuring Menstrual Iron Loss Using the Iron Isotope Dilution Technique

MBL_Loss
Start date: March 1, 2023
Phase:
Study type: Observational

It is very difficult to quantify menstrual blood loss, the reference method is a tedious one. This is a problem, as it is not conducive to objectively measuring menstrual blood loss and understanding the contribution of menstrual iron loss to iron deficiency anemia. With this study, the investigators aim to investigate iron loss during the menstrual cycle and aim to validate a much simpler technique.

NCT ID: NCT05406960 Completed - Hysterectomy Clinical Trials

Therapeutic Effect of Herbal Infusion on Menometrorrhagia

HERBALTREAT
Start date: May 10, 2019
Phase: N/A
Study type: Interventional

This is an interventional, non-randomized, controlled, pilot study that explores a new approach to treat, Abnormal uterine bleeding-menometrorrhagia in women, being candidates for hysterectomy, based on tea infusion consumption of a mixture of two plants.

NCT ID: NCT05176496 Completed - Clinical trials for Heavy Menstrual Bleeding

A Study Called Champion-HMB to Learn More About Females With Heavy Menstrual Bleeding and Available Treatments to Enable Earlier Diagnosis and to Predict Courses of Treatment

Champion-HMB
Start date: November 30, 2021
Phase:
Study type: Observational

This is an observational study in which patient data from the past of females with heavy menstrual bleeding (HMB) is studied. • HMB describes menstrual periods with abnormally heavy or prolonged bleeding. Women concerned may not be able to maintain their usual activities during their period. Thus, HMB can reduce the quality of life and may lead to other medical problems. It is described that up to 30 of 100 women ask doctors for help concerning HMB during their fertile years. HMB is often not recognized and treated timely. In addition, there is little information about characteristics of women with HMB and real-world data on available treatments are missing. Despite the availability of non-invasive therapeutic options, for some women with severe HMB, surgical treatments (also called invasive) may be needed that can lead to infertility. - In this study researchers want to learn more about: - the percentage of women diagnosed with HMB - characteristics of these women like age at diagnosis or medical problems - treatment pathways of women with HMB in usual care Regarding treatment pathways, the researchers are especially interested in: - the percentage of women who use different therapeutic options over time - the percentage of women receiving invasive treatment for HMB after they received treatment as recommended by guidelines versus those not treated as recommended - To do this, researchers will collect information from five observational healthcare databases. Data will be from the year 2000 up to 2020. - Besides this data collection, no further tests or examinations are planned in this study. - In future, this information shall help to identify women with HMB and to learn what information may predict if invasive treatment will be needed later on.

NCT ID: NCT05007899 Completed - Clinical trials for Iron Deficiency Anemia

Alternate Day Versus Daily Oral Iron Therapy in Adolescents

Start date: December 21, 2020
Phase: Phase 4
Study type: Interventional

Iron deficiency anemia affects over half of girls and young women with heavy periods and is the most common cause of anemia worldwide. Most girls with heavy periods who also have iron deficiency anemia are prescribed iron to take by mouth every day by their doctor. There are some studies showing that taking iron every other day may actually help the iron be absorbed into the bloodstream better. This study is trying to compare how taking iron every other day compares to taking iron daily for treatment of anemia. The goal of this clinical research study is to learn which of the two methods of care will be the best way for girls and young women with iron deficiency anemia to take iron supplementation.

NCT ID: NCT04425577 Completed - Contraception Clinical Trials

Ultrasound Evaluation Versus Direct Measurement of Uterine Cavity Length

Start date: January 6, 2020
Phase: N/A
Study type: Interventional

To determine if uterine cavity length on transabdominal pelvic ultrasound corresponds to uterine cavity length at time of IUD insertion. If transabdominal pelvic ultrasound is validated as a tool for measuring uterine cavity length, it can be used to guide physicians and subsequently patients in IUD insertion planning.

NCT ID: NCT03886220 Completed - Uterine Fibroids Clinical Trials

A Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

Start date: April 12, 2019
Phase: Phase 4
Study type: Interventional

The main objective of this study is to assess safety and efficacy of elagolix compared to placebo in reducing heavy menstrual bleeding (HMB) associated with uterine fibroids in premenopausal women. The primary hypothesis is that elagolix, compared to placebo, reduces HMB associated with uterine fibroids in premenopausal women.

NCT ID: NCT03794895 Completed - Clinical trials for Women's Health: Amenorrhea/Dysmenorrhea

Prediction of Response to IUCD Associated Menorrhagia Using Doppler

Start date: May 1, 2017
Phase: N/A
Study type: Interventional

Studying the efficacy of uterine artery doppler in predicting response to mefenamic acid in women having IUCD associated menorrhagia

NCT ID: NCT03751800 Completed - Menorrhagia Clinical Trials

A Study Run at Multiple Study Sites to Test Whether the SAMANTA Questionnaire That is Used to Diagnose Heavy Menstrual Bleeding (HMB), Can Also be Used to Assess Changes of Severity of HMB in Women With HMB Who Are Treated During 12 Months With a Chronic Hormonal Treatment

SAMIRA
Start date: December 12, 2018
Phase:
Study type: Observational

A study run at multiple study sites in Spain to test whether the SAMANTA questionnaire that is used to diagnose heavy menstrual bleeding (HMB), can also be used to assess changes of severity of HMB in women with HMB who are treated during 12 months with a chronic hormonal treatment. Patients that are treated with chronic hormonal treatment as Levonorgestrel (trade name Mirena) or with a combination of estradiol valerate and dienogest (trade name Qlaira) or with Medroxyprogesterone acetate (trade name Progevera) and any new hormonal treatment marketed in Spain that has the indication for HMB in routine gynaecological practice are observed for 12 months in this study or for a shorter period in time in case of withdrawal. The study aims also to describe the overall satisfaction of women with their chronic hormonal treatment for HMB and how the women think their menstrual bleeding has changed. In addition the study aims to describe the changes of the score that is derived from the SAMANTA questionnaire in relation to Quality of Life. Quality of Life is measured with the SF36v2 questionnaire. The Short Form (36) Health Survey is a 36-item, patient-reported survey of patient health.

NCT ID: NCT03751124 Completed - Uterine Fibroids Clinical Trials

Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Start date: October 16, 2018
Phase: Phase 3
Study type: Interventional

The objectives of this randomized withdrawal study are to evaluate the long-term efficacy and safety of the combination of relugolix, estradiol (E2) and norethindrone acetate (NETA), once daily, for up to 104 weeks in patients with uterine fibroids who have completed a total of 52 weeks of treatment, including a 24-week treatment period in a parent study (study MVT-601-3001 or MVT-601-3002) and a 28-week treatment period in the open-label extension study (MVT-601-3003), and who meet the definition of responder, defined as a patient who demonstrates a menstrual blood loss of < 80 mL and at least a 50% reduction from parent study baseline menstrual blood loss volume on the alkaline hematin analysis of the feminine products returned at Week 48 in the extension study.

NCT ID: NCT03642210 Completed - Menorrhagia Clinical Trials

Study of a Levonorgestrel 52 mg Intrauterine System for the Treatment of Heavy Menstrual Bleeding

Start date: January 17, 2019
Phase: Phase 3
Study type: Interventional

To assess the efficacy of a levonorgestrel 52 mg intrauterine system as a treatment for heavy menstrual bleeding.